Publications by authors named "P A De Mulder"
Fatal acute pulmonary embolism following endoscopic cyanoacrylate injection for gastric fundal varices.
Acta Gastroenterol Belg
January 2025
Acute gastric variceal bleeding is a rare but serious complication of portal hypertension. Initial therapy for bleeding gastric varices focuses on acute hemostasis. In this regard, endoscopic cyanoacrylate injection (ECI) is the first-line approach.
View Article and Find Full Text PDFArticle Synopsis
- - Patients with chronic kidney disease (CKD) are at increased risk for heart-related issues, and medications like SGLT2 inhibitors (Dapagliflozin) and MRAs (Eplerenone) can help with cardiovascular problems, especially in diabetic cases.
- - A study tested the effects of Dapagliflozin and Eplerenone together on heart and kidney functions in rats with non-diabetic CKD, revealing that both drugs reduced kidney fibrosis and improved heart pressure and perfusion.
- - The combined treatment of Dapagliflozin and Eplerenone not only improved heart function but also showed a synergetic effect in reducing heart muscle damage compared to using each drug alone.
Objectives: To determine the prevalence, trends, and potential nosocomial transmission events of the hidden reservoir of rectal carriage of extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-E).
Methods: From 2013 to 2022, yearly point prevalence surveys were conducted in a large Dutch teaching hospital. On the day of the survey, all admitted patients were screened for ESBL-E rectal carriage using peri-anal swabs and a consistent and sensitive selective culturing method.
Natural toxins (NTs) are poisonous secondary metabolites produced by living organisms developed to ward off predators. Especially low molecular weight NTs (MW<∼1 kDa), such as mycotoxins, phycotoxins, and plant toxins, are considered an important and growing food safety concern. Therefore, accurate risk assessment of food and feed for the presence of NTs is crucial.
View Article and Find Full Text PDFBackground: The mineralocorticoid receptor plays a significant role in the development of chronic kidney disease (CKD) and associated cardiovascular complications. Classic steroidal mineralocorticoid receptor antagonists are a therapeutic option, but their use in the clinic is limited due to the associated risk of hyperkalemia in patients with CKD. Finerenone is a nonsteroidal mineralocorticoid receptor antagonist that has been recently investigated in 2 large phase III clinical trials (FIDELIO-DKD [Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease] and FIGARO-DKD [Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease]), showing reductions in kidney and cardiovascular outcomes.
View Article and Find Full Text PDF